Table 5.
Cost analysis in modified intention-to-treat patients grouped as defined per bacteriologic documentation (visit 2)
| Group I (n = 113, 46.3%) | Group II (n = 14, 5.7%) | Group III (n = 38, 15.6%) | Group IV (n = 56, 23.0%) | Group V (n = 23, 9.4%) | Overall (n = 244, 100%) | Kruskal–Wallis P value | |
| Hospital admission (days) | 23.8 (39.9) | 19.9 (19.9) | 22.1 (36.0) | 14.9 (19.0) | 33.8 (81.2) | 22.3 (40.9) | 0.46 |
| ICU admission (days) | 20.5 (34.1) | 34.0 (32.2) | 36.7 (24.2) | 23.7 (14.5) | 17.8 (79.0) | 24.3 (36.4) | <0.001 |
| Costs of hospitalization in the general ward (€) | 4,983.40 (8,754.20) | 4,160.47 (4,461.11) | 4,835.13 (8,023.24) | 2,983.81 (4,164.14) | 7,264.92 (8.754.20) | 4,669.23 (8,971.35) | 0.44 |
| Costs of ICU admission (€) | 6,725.70 (11,412.94) | 11,469.22 (10,872.13) | 12,055.11 (8,283.93) | 7,860.99 (4,965.19) | 5,749.28 (26,069.12) | 7,996.38 (12,182.74) | 0.001 |
| Antibiotic acquisition costs (€) | 539.98 (2,636.00) | 533.03 (622.62) | 487.49 (1,002.59) | 322.06 (300.38) | 360.09 (446.92) | 464.44 (1,850.30) | 0.97 |
| Other therapeutic and diagnostic procedures (€) | 631.26 (462.19) | 591.61 (278.65) | 853.59 (531.50) | 652.41 (399.60) | 855.75 (513.94) | 689.63 (463.63) | 0.04 |
| Total costs per episode (€) | 12,880.35 (9,420.68) | 16,754.33 (10,977.94) | 18,231.32 (13,402.92) | 11,819.28 (7,007.02) | 14,230.04 (10,571.25) | 13,819.67 (10,041.06) | 0.01 |
| Total daily costs (€) | 324.05 (102.29) | 327.16 (41.17) | 337.95 (46.27) | 332.19 (39.40) | 301.22 (156.78) | 326.07 (89.22) | 0.35 |
Data presented as mean (standard deviation). ICU, intensive care unit. Costs were estimated using drug label information and data published by Institut Municipal d'Assistència Sanitària and Laboratori de Referència de Catalunya (Barcelona, Spain) updated through 2001. Group I, patients with an unknown aetiology and unmodified therapy; Group II, patients with resistant organisms, who had unmodified therapy; Group III, patients with susceptible organisms, who had unmodified therapy; Group IV, patients who had susceptible organisms and whose therapy was modified accordingly; and Group V, patients who initially received inadequate antibiotic therapy, which was later modified on the basis of cultures.